Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 80, Issue 5, Pages 895-907Publisher
SPRINGER
DOI: 10.1007/s00280-017-3392-8
Keywords
Electrolyte; Platinum; Chemotherapy; Cisplatin; Toxicity
Categories
Ask authors/readers for more resources
Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. The corpus of literature on these dyselectrolytemias is large; the objective of this review is to synthesize the literature and summarize the mechanisms responsible for these particular electrolyte disturbances in the context of platinum-based treatment as well as to present the clinical manifestations and current management strategies for oncologists and primary care physicians, since the latter are increasingly called on to provide care for cancer patients with medical comorbidities. Correct diagnosis and effective treatment are essential to improved patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available